Recently, translocationand cyclin (TC) classification of MM has been introduced;the classification is based on cyclin expression types [16].Thus, CDK inhibitors have a potential role in the treatmentof MM, including PD 0332991, a specific inhibitorof CDK4/6, and seliciclib, UCN-01, P276-00, AT7519,and RGB 286638, non-specific CDK inhibitors [12]. Here, CDK4 is linked to Miyoshi myopathy.